Armata Pharmaceuticals receives additional USD 2.5 million DoD funding for AP-SA02 program

Innoviva, Inc.
Armata Pharmaceuticals

Innoviva, Inc.

INVA

0.00

Armata Pharmaceuticals

ARMP

0.00
  • Armata Pharmaceuticals received USD 2.5 million in additional non-dilutive U.S. Department of Defense funding for AP-SA02.
  • Total DoD support for the program reached USD 28.7 million; funds target Phase 3 readiness in complicated Staphylococcus aureus bacteremia.
  • Award flows through the Medical Technology Enterprise Consortium; program managed by the Naval Medical Research Command.
  • Armata targets a Phase 3 superiority study start in 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606230700PR_NEWS_USPR_____LA89675) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.